Literature DB >> 19785655

Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.

A Takahara1, Y Nakamura, H Wagatsuma, S Aritomi, A Nakayama, Y Satoh, Y Akie, A Sugiyama.   

Abstract

BACKGROUND AND
PURPOSE: The heart of the canine model of chronic atrioventricular block is known to have a ventricular electrical remodelling, which mimics the pathophysiology of long QT syndrome. Using this model, we explored a new pharmacological therapeutic strategy for the prevention of cardiac sudden death. EXPERIMENTAL APPROACH: The L-type Ca(2+) channel blocker amlodipine (2.5 mg.day(-1)), L/N-type Ca(2+) channel blocker cilnidipine (5 mg.day(-1)), or the angiotensin II receptor blocker candesartan (12 mg.day(-1)) was administered orally to the dogs with chronic atrioventricular block for 4 weeks. Electropharmacological assessments with the monophasic action potential (MAP) recordings and blood sample analyses were performed before and 4 weeks after the start of drug administration. KEY
RESULTS: Amlodipine and cilnidipine decreased the blood pressure, while candesartan hardly affected it. The QT interval, MAP duration and beat-to-beat variability of the ventricular repolarization period were shortened only in the cilnidipine group, but such effects were not observed in the amlodipine or candesartan group. Plasma concentrations of adrenaline, angiotensin II and aldosterone decreased in the cilnidipine group. In contrast, plasma concentrations of angiotensin II and aldosterone were elevated in the amlodipine group, whereas in the candesartan group an increase in plasma levels of angiotensin II and a decrease in noradrenaline and adrenaline concentrations were observed. CONCLUSIONS AND IMPLICATIONS: Long-term blockade of L/N-type Ca(2+) channels ameliorated the ventricular electrical remodelling in the hypertrophied heart which causes the prolongation of the QT interval. This could provide a novel therapeutic strategy for the treatment of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19785655      PMCID: PMC2782346          DOI: 10.1111/j.1476-5381.2009.00407.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

2.  Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling.

Authors:  M A Vos; S H de Groot; S C Verduyn; J van der Zande; H D Leunissen; J P Cleutjens; M van Bilsen; M J Daemen; J J Schreuder; M A Allessie; H J Wellens
Journal:  Circulation       Date:  1998-09-15       Impact factor: 29.690

3.  Effect of cilnidipine, a novel dihydropyridine Ca2+ channel blocker, on adrenal catecholamine secretion in anesthetized dogs.

Authors:  T Nagayama; M Yoshida; M Suzuki-Kusaba; H Hisa; T Kimura; S Satoh
Journal:  J Cardiovasc Pharmacol       Date:  1998-09       Impact factor: 3.105

Review 4.  Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes.

Authors:  Charles Antzelevitch
Journal:  Europace       Date:  2007-09       Impact factor: 5.214

5.  Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease.

Authors:  Veena Raizada; Betty Skipper; Wentao Luo; Luis Garza; Curt W Hines; Antonia A Harford; Philip G Zager; Jeffrey Griffith; Dominic Raj; Charles T Spalding
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

6.  Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization.

Authors:  Morten B Thomsen; Michiel Truin; Jurren M van Opstal; Jet D M Beekman; Paul G A Volders; Milan Stengl; Marc A Vos
Journal:  Basic Res Cardiol       Date:  2005-03-09       Impact factor: 17.165

7.  Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone.

Authors:  Akira Takahara; Yuji Nakamura; Atsushi Sugiyama
Journal:  Eur J Pharmacol       Date:  2008-08-30       Impact factor: 4.432

Review 8.  Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.

Authors:  Akira Takahara
Journal:  Cardiovasc Ther       Date:  2009       Impact factor: 3.023

9.  Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor.

Authors:  Y H Wang; C X Shi; F Dong; J W Sheng; Y F Xu
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

10.  Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.

Authors:  T Fujita; K Ando; H Nishimura; T Ideura; G Yasuda; M Isshiki; K Takahashi
Journal:  Kidney Int       Date:  2007-10-17       Impact factor: 10.612

View more
  13 in total

Review 1.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

2.  L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.

Authors:  Shizuka Aritomi; Tomoyuki Konda; Michihiro Yoshimura
Journal:  Heart Vessels       Date:  2011-10-12       Impact factor: 2.037

3.  An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation.

Authors:  Kazuko Tajiri; Jean-Baptiste Guichard; Xiaoyan Qi; Feng Xiong; Patrice Naud; Jean-Claude Tardif; Antoine Da Costa; Kazutaka Aonuma; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

4.  L/N-type Ca2+ channels blocker cilnidipine ameliorated the repolarization abnormality in a chronic hemodialysis patient.

Authors:  Xin Cao; Yuji Nakamura; Takeshi Wada; Hiroko Izumi-Nakaseko; Kentaro Ando; Atsushi Sugiyama
Journal:  Heart Vessels       Date:  2016-06-20       Impact factor: 2.037

5.  Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.

Authors:  Shizuka Aritomi; Kazumi Niinuma; Tetsuya Ogawa; Tomoyuki Konda; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-08-17       Impact factor: 2.801

Review 6.  Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers: A Meta-Analysis of Randomized Controlled and Retrospective Studies.

Authors:  Mayakalyani Srivathsan; Vikram Vardhan; Azra Naseem; Sayali Patil; Vivek Rai; Deepakkumar G Langade
Journal:  Cureus       Date:  2022-08-10

7.  L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.

Authors:  Masanori Abe; Noriaki Maruyama; Hiroko Suzuki; Atsushi Inoshita; Yoshinori Yoshida; Kazuyoshi Okada; Masayoshi Soma
Journal:  Heart Vessels       Date:  2012-08-23       Impact factor: 2.037

8.  Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.

Authors:  Mitsuru Masaki; Toshiaki Mano; Akiyo Eguchi; Shohei Fujiwara; Masataka Sugahara; Shinichi Hirotani; Takeshi Tsujino; Kazuo Komamura; Masahiro Koshiba; Tohru Masuyama
Journal:  Heart Vessels       Date:  2016-01-29       Impact factor: 2.037

9.  Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.

Authors:  Shizuka Aritomi; Eri Harada; Kazumi Sugino; Mai Nishimura; Tarou Nakamura; Akira Takahara
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-04       Impact factor: 2.557

Review 10.  The canine chronic atrioventricular block model in cardiovascular preclinical drug research.

Authors:  Vera Loen; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2021-05-04       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.